Yuri Deigin - Partial Reprogramming Drug Development for Aging
The Bioinformatics CRO Podcast
00:00
Aging and Biomarkers of Aging in Drug Development?
I think we have enough at this point enough biomarkers to assess to a pretty good degree any interventions that claim to rejuvenate or slow down aging. So from that standpoint, I don't think there's anything limiting drug development or therapy development for rejuvenating therapies.
Play episode from 08:37
Transcript
